RT @biodomtomi: Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-…
65 followers
137 followers
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial - The Lancet Oncology #NSCLC #ALK #ROS https://t.co/IEaLKrgu3p
1,119 followers
RT @VivekSubbiah: Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, singl…
7,681 followers
RT @VivekSubbiah: Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, singl…